• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Science. Author manuscript; available in PMC Sep 24, 2007.
Published in final edited form as:
PMCID: PMC1991296
NIHMSID: NIHMS29209

A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

Abstract

Understanding why some people establish and maintain effective control of HIV-1 and others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection. One of these is found within an endogenous retroviral element and is associated with major histocompatibility allele human leukocyte antigen (HLA)–B*5701, whereas a second is located near the HLA-C gene. An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit. These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents.

Humans show remarkable variation in vulnerability to infection by HIV-1 and especially in the clinical outcome after infection. One striking and largely unexplained difference is the level of circulating virus in the plasma during the nonsymptomatic phase preceding the progression to AIDS. This is known as the viral set point and can vary among individuals by as much as 4 to 5 logs (16). We aimed to identify human genetic differences that influence this variation.

To define a homogeneous phenotype for genetic analyses, a consortium of nine cohorts was formed [termed Euro-CHAVI (Center for HIV/AIDS Vaccine Immunology) (7)], and a total of 30,000 patients were screened to identify those most appropriate for analysis. All longitudinal viral-load (VL) data were assessed through a computerized algorithm to eliminate VL not reflecting the steady state and were individually inspected by an experienced infectious-disease clinician (Fellay) to exclude suspicious VL data and patients that do not show a clear set point, leaving 486 patients with a consistent and accurately measured phenotype (7). For patients with at least four CD4 cell-count results, we defined a progression phenotype as the time to treatment initiation or to the predicted or observed drop of the CD4 cell count below 350 (7, 8).

All samples were genotyped with the use of Illumina's HumanHap550 BeadChip with 555,352 single-nucleotide polymorphisms (SNPs). A series of quality-control steps resulted in the elimination of 20,251 polymorphisms (7). We applied methods to identify deletions and targeted copy-number variations and to assess whether they influenced the phenotype (7). Our core association analyses focused on single-marker genotype-trend tests of the quality control–passed SNPs, using linear regression (7). To control for the possibility of spurious associations resulting from population stratification, we used a modified EIGENSTRAT method (7, 9). We assessed significance with a Bonferroni correction (P cutoff = 9.3 × 10−8). Analyses incorporating human leukocyte antigen (HLA) typing were carried out on a subgroup of 187 patients with available four-digit HLA class I allelic determination.

These analyses identified two independently acting groups of polymorphisms, associated with HLA loci B and C, that are estimated to explain 9.6 and 6.5% of the total variation in HIV-1 set point, respectively, and can thus be considered as major genetic determinants of viral set point. A third set located >1 Mb away in the major histocompatibility complex upstream of a gene that encodes an RNA polymerase I subunit explains 5.8% of the total variation in disease progression. Together, the three polymorphisms explain 14.1% of the variation in HIV-1 set point.

One polymorphism located in the HLA complex P5 (HCP5) gene explains 9.6% of the total variation in set point, despite a minor-allele frequency of 0.05 (Single Nucleotide Polymorphism database number rs2395029, P = 9.36 × 10−12). A single copy of the controlling allele was found to result in a reduction in VL of >1 log (Fig. 1); at P = 9.36 × 10−12, this genome-wide association is significant.

Fig. 1
HIV-1 VL at the set point is highly correlated with (A) the HCP5 rs2395029 genotype, where T is the major allele and G is the minor allele, and with (B) the HLA-C 5′ region rs9264942 genotype, where T is the major allele and C is the minor allele. ...

The HCP5 gene is located 100 kb centromeric from HLA-B on chromosome 6 (Fig. 2), and the associated variant is known to be in high linkage disequilibrium (LD) with the HLA allele B*5701 (10) (r2 = 1 in our data set). This allele itself has the strongest-described protective impact on HIV-1 disease progression (11) and has been associated with low VL (12).

Fig. 2
Partial map of the HLA class I region (chromosome 6 p21.3). The P values [−log(P)] of all genotyped SNPs annotated with the gene structure are indicated. The two independent SNPs that show genome-wide significant association with HIV-1 VL at the ...

Given the strong functional data supporting a role for HLA-B*5701 in restricting HIV-1, our first hypothesis is that the association observed here is due to the effect of HLA-B*5701, reflected in its tagging a SNP within HCP5 (10). We emphasize, however, that genetics allows no resolution of whether this effect is exclusively due to B*5701 or if HCP5 variation also contributes to the control. In fact, as a human endogenous retroviral element (HERV) with sequence homology to retroviral pol genes (13) and confirmed expression in lymphocytes (14), HCP5 is itself a good candidate to interact with HIV-1, possibly through an antisense mechanism (14). Moreover, HCP5 is predicted to encode two proteins, and the associated polymorphism results in an amino acid substitution in one of these proteins.

A model in which HCP5 and HLA-B*5701 have a combined haplotypic effect on the HIV-1 set point is consistent with the observation that suppression of viremia can be maintained in B*5701 patients with undetectable VL, even after HIV-1 undergoes mutations that allow escape from cytotoxic T lymphocyte (CTL)–mediated restriction (15). However, this observation has also been explained by a decrease in viral fitness associated with the escape variants (16). In addition, B*5701 patients present less frequently with symptoms during acute HIV-1 infection (12), suggesting control before the time of a maximal CTL response (17).

The second most significant polymorphism we identified, rs9264942, is located in the 5′ region of the HLA-C gene, 35 kb away from transcription initiation (Fig. 2) and 156 kb telomeric of the HCP5 gene. This SNP explains 6.5% of the variation in set point (Fig. 1) and shows a genome-wide significant association (P = 3.77 × 10−9). Despite minor LD between the HCP5 and HLA-C SNPs (r2 = 0.05, D′ = 0.84), nested regression models clearly demonstrate an independent effect of each of these variants. In a model including the HCP5 variant, the addition of the HLA-C variant results in a highly significant increase in explanatory power, as does the addition of the HCP5 variant to a model already including the HLA-C variant [supporting online material (SOM) text].

This SNP also associates strongly with differences in HLA-C expression levels, both in the Sanger Institute Genevar expression database (18) (table S1) and in a replication group of 48 healthy volunteers established for this study (SOM text). The protective allele leads to a lower VL and is associated with higher expression of the HLA-C gene. This strong and independent association with HLA-C expression levels suggests that genetic control of expression levels of a classical HLA gene influences viral control. Other HLA-C 5′ variants also associate with HLA-C expression but do not contribute independently to viral control (SOM text).

Although these data make a strong case for a causal role for HLA-C expression levels, extensive LD throughout the MHC region makes it necessary to directly test for alternative causal variants. Specifically, we used nested regression models to assess whether the observed association could be determined by described functional HLA class I alleles. In fact, the HLA-C expression SNP shows association with certain alleles or group of alleles (Tables 1 and and2).2). In each case, however, although the HLA-C expression variant can explain the effect of these alleles on the HIV-1 set point, the reverse is not true. When a linear regression model includes known HLA alleles, the addition of rs9264942 results in a significant increase in the explained variation. On the other hand, none of the HLA alleles considered, with the exception of HCP5/B*5701, adds significantly to a model that already incorporates the HLA-C variant (Tables 1 and and22).

Table 1
The impact of HLA-C 5′ expression polymorphism rs9264942 on the set point is independent of its association with HLA alleles and groups of alleles previously implicated in HIV-1 control. The addition of rs9264942 to the linear regression model ...
Table 2
In contrast to Table 1, only HLA-B*5701 has an independent impact after taking into account the effect of rs9264942. The independence of HLA-C is also clearly seen in the mean values of the HIV-1 set point for each rs9264942 genotype: The minor allele ...

No other single marker reached genome significance, and none of the identified copy-number variations (7) showed any association with the HIV-1 set point. An analysis comparing the observed set of P values to that expected under the null hypotheses shows no overall inflation of P values (indicating little contribution from population stratification) but does show an excess of low P values, beginning with the 355th most associated SNP (fig. S1). This indicates that additional real effects are likely to be present among the most associated polymorphisms in this study (complete list available in table S2). Potentially interesting candidates with a lesser association with the set point (listed in tables S3 to S5) were chosen on the basis of their ranking in the study or their link with HIV-1 biology.

We next identified polymorphisms that associate with progression rather than VL: The strongest association included a set of seven polymorphisms located in and near the ring finger protein 39 (RNF39) and zinc ribbon domain–containing 1 (ZNRD1) genes, respectively (rs9261174, rs3869068, rs2074480, rs7758512, rs9261129, rs2301753, and rs2074479). This group of polymorphisms explains 5.8% of the variation in progression, with a relative hazard of 0.64 (fig. S2), and approaches genome-wide significance (P = 3.89 × 10−7). It also associates with VL at the set point (P = 7.11 × 10−3). These variants are >1 Mb telomeric from the previous candidates (fig. S3), and their effect on both progression and set point is independent of HCP5- and HLA-C–related polymorphisms and HLA alleles or groups of alleles previously implicated in HIV-1 control (SOM text and table S6).

Using the Genevar database and our group of 48 healthy volunteers, we observed that ZNRD1 expression is significantly associated with the identified SNPs (SOM text and table S1). Two of them (rs3869068 and rs9261174) are located in a putative regulatory 5′ region, 25 and 32 kb away from the gene, respectively. Because ZNRD1 encodes an RNA polymerase I subunit, if this gene is responsible for the restriction of HIV-1, the mechanism could involve interference with the processing of HIV-1 transcripts by the HIV-1 regulatory protein Rev. Rev is known to be localized in the nucleolus (where RNA polymerase I transcribes ribosomal RNA), and the blockade of RNA polymerase I has been shown to influence the distribution of REV, causing a shift from the nucleolus to the cytoplasm (19, 20). Efficiency in provirus transcription is highly variable among individuals; in one study, differences in transcription efficiency accounted for 64 to 83% of the total variance in virus production that was attributable to post-entry cellular factors (21).

The second gene, RNF39, is poorly characterized but cannot be ruled out as a candidate because two of the associated polymorphisms are located in its coding region and result in amino acid changes (rs2301753 and rs2074479). No other genome-wide significant association was observed in the analysis of the progression phenotype (SOM text).

We established an independent replication cohort of 140 Caucasian patients, drawn from the same participating cohorts. For this follow-up study, we relaxed the interval from a documented negative test to a positive test (for infection) from 2 years to 4 years to identify additional qualifying study participants. We genotyped representative polymorphisms for the associations reported above (HCP5, rs2395029; HLA-C, rs9264942; and ZNRD1, rs9261174). Each association was replicated with effects all in the same direction: HCP5, P = 1.4 × 10−2; HLA-C, P = 2.8 × 10−3; and ZNRD1, P = 4.8 × 10−2.

We have securely identified at least two mechanisms not previously known to restrict HIV-1: HLA-C, which has been suspected but never confirmed to contribute to HIV-1 control, and an RNA polymerase subunit that substantially changes the time course of HIV progression (fig. S1). We also suggest the possibility that a HERV-derived gene may contribute to the viral control attributed to the HLA-B*5701 allele. Our findings confirm and emphasize the central role of the MHC region in HIV-1 restriction, estimate its contribution against all genome influences, and open up new perspectives in the understanding of its mode of action: It is necessary to expand HLA analysis to include high-density genotyping. It is also noteworthy that this genome-wide study of host determinants has three clear discoveries, implying that determinants of host response may often include gene variants with major effects. This suggests a degree of urgency in carrying out similar studies for other infectious diseases.

Our results suggest two possible directions for therapeutic intervention. First, if HCP5 and ZNRD1 contribute to the control associated with HLA-B*5701, they could lead to therapeutic applications. On the other hand, the implication of HLA-C in HIV-1 control could present important opportunities, given that the HIV-1 accessory protein Nef selectively down-regulates the expression of HLA-A and -B but not that of HLA-C on the surface of infected cells (22). Originally, this strategy was considered advantageous for the virus because HLA-A and -B present foreign (notably viral) epitopes to CD8 T cells, resulting in cell destruction, whereas HLA-C binds self-peptides and interacts with natural killer (NK) cells to avoid NK attack. However, HLA-C also has the ability to present viral peptides to cytotoxic CD8+ T cells and consequently to restrict HIV-1 (23, 24). Our observations suggest that HLA-C–mediated restriction may be an important element of viral control in specific genetic backgrounds, and that the apparent immunity of HLA-C to Nef down-regulation could present an opportunity for vaccine strategies targeting HLA-C–mediated responses.

Footnotes

References and Notes

1. Telenti A, Goldstein DB. Nat Rev Microbiol. 2006;4:865. [PMC free article] [PubMed]
2. O'Brien SJ, Nelson GW. Nat Genet. 2004;36:565. [PubMed]
3. Telenti A, Bleiber G. Future Virol. 2006;1:55.
4. Carrington M, O'Brien SJ. Annu Rev Med. 2003;54:535. [PubMed]
5. Nelson GW, O'Brien SJ. J Acquired Immune Defic Syndr. 2006;42:347. [PubMed]
6. Bleiber G, et al. J Virol. 2005;79:12674. [PMC free article] [PubMed]
7. Materials and methods are available as supporting material on Science Online.
8. Douek DC, Picker LJ, Koup RA. Annu Rev Immunol. 2003;21:265. [PubMed]
9. Price AL, et al. Nat Genet. 2006;38:904. [PubMed]
10. de Bakker PI, et al. Nat Genet. 2006;38:1166. [PMC free article] [PubMed]
11. Migueles SA, et al. Proc Natl Acad Sci USA. 2000;97:2709. [PMC free article] [PubMed]
12. Altfeld M, et al. AIDS. 2003;17:2581. [PubMed]
13. Kulski JK, Dawkins RL. Immunogenetics. 1999;49:404. [PubMed]
14. Vernet C, et al. Immunogenetics. 1993;38:47. [PubMed]
15. Bailey JR, et al. J Exp Med. 2006;203:1357. [PMC free article] [PubMed]
16. Martinez-Picado J, et al. J Virol. 2006;80:3617. [PMC free article] [PubMed]
17. McMichael AJ, Rowland-Jones SL. Nature. 2001;410:980. [PubMed]
18. Stranger BE, et al. PLoS Genet. 2005;1:e78. [PMC free article] [PubMed]
19. Michienzi A, et al. Proc Natl Acad Sci USA. 2000;97:8955. [PMC free article] [PubMed]
20. Dundr M, et al. J Cell Sci. 1995;108:2811. [PubMed]
21. Ciuffi A, et al. J Virol. 2004;78:10747. [PMC free article] [PubMed]
22. Cohen GB, et al. Immunity. 1999;10:661. [PubMed]
23. Goulder PJ, et al. AIDS. 1997;11:1884. [PubMed]
24. Adnan S, et al. Blood. 2006;108:3414. [PMC free article] [PubMed]
25. We thank R. Sahli (University of Lausanne, Switzerland). Funding was provided by the NIH-funded Center for HIV/AIDS Vaccine Immunology. J.F. is supported by the Swiss Foundation for Grants in Biology and Medicine, and A.T. is supported by Infectigen and the Swiss National Science Foundation.
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Gene
    Gene
    Gene links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene
    HomoloGene links
  • MedGen
    MedGen
    Related information in MedGen
  • Protein
    Protein
    Published protein sequences
  • PubMed
    PubMed
    PubMed citations for these articles
  • SNP
    SNP
    PMC to SNP links
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...